Clinical Trials Browser

GRN163L peptide × Clear all

Leukemia, Myeloid, Acute

NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1 Recruiting

36 enrolled

Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 2 FDA

Myeloid

Myelodysplastic Syndromes, Recurrence

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

327 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT05583552 2025-03-14

IMpress

Phase 2 Active not recruiting

46 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2 Completed

80 enrolled 31 charts

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 2 Withdrawn

CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Phase 2 Terminated

43 enrolled 14 charts

CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

NCT01242930 2016-05-12

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Phase 2 Completed

13 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01137968 2016-01-26

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

116 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01256762 2016-01-26

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2 Completed

166 enrolled

Breast

Breast Neoplasms

NCT00124189 2015-12-24

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Phase 1 Completed

48 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

NCT00732056 2015-12-24

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

Phase 1 Completed

24 enrolled

Breast

Breast Neoplasms

Clinical Trials

IMAGINE

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

IMpress

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer